Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IIOngoingAug 26, 2026AMINAOCAPROIC ACID INJECTIONPresence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehydeAmerican Regent, Inc. · D-0794-2026Class IIOngoingAug 26, 2026Cyanocobalamin injection USPPresence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehydeAmerican Regent, Inc. · D-0793-2026Class IIOngoingAug 26, 2026Cyanocobalamin injection USPPresence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehydeAmerican Regent, Inc. · D-0792-2026Class IIOngoingAug 26, 2026Nitroglycerin injectionPresence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehydeAmerican Regent, Inc. · D-0791-2026Class IOngoingAug 26, 2026Morphine Sulfate InjectionLabeling: Label Mixup: MicroVault labeled as Morphine 2 mg/1 mL, contains a Prefilled Syringe of Dilaudid 0.5 mg/0.5 mL.Fresenius Kabi USA, LLC · D-0788-2026Class IIOngoingAug 26, 2026Acamprosate CalciumFailed Dissolution SpecificationsMylan Pharmaceuticals Inc · D-0774-2026Class IIOngoingAug 26, 2026Carbamazepine TabletsCGMP deviations: tablets with black specks.Golden State Medical Supply Inc. · D-0771-2026Class IIOngoingAug 26, 2026Carbamazepine TabletsCGMP Deviations; black spots found on tablets from burnt excipient during manufacturingSun Pharmaceutical Industries Inc · D-0770-2026Class IIOngoingAug 26, 2026LibtayoLack of Assurance of SterilityRegeneron Pharmaceuticals Inc · D-0767-2026Class IIOngoingAug 26, 2026PEMRYDI RTUDiscolored solution. The firm has received market complaints reporting green to dark green discoloration in certain vialsShilpa Medicare Limited · D-0765-2026Class IIOngoingAug 26, 2026PEMRYDI RTUDiscolored solution. The firm has received market complaints reporting green to dark green discoloration in certain vialsShilpa Medicare Limited · D-0764-2026Class IOngoingAug 19, 2026Cefazolin in DextrosePresence of Particulate MatterBaxter Healthcare Corporation · D-0787-2026Class IOngoingAug 19, 2026Optiray Imaging Bulk Package-350Presence of Particulate Matter: comprising polyethylene and other plastic materials, stainless steel and glass.Liebel-Flarsheim Company LLC · D-0773-2026Class IOngoingAug 19, 2026GlutathioneMicrobial Contamination of Sterile Products - out of specifications results were obtained for bacterial endotoxin.Victory Medical Center Pharmacy · D-0772-2026Class IOngoingAug 19, 2026Kian Pee Wan CapsulesMarketed Without an Approved NDA/ANDA: Product contains undeclared drug ingredients dexamethasone and cyproheptadine.Buy-Herbal · D-0769-2026Class IIOngoingAug 19, 2026CLINDAMYCIN PALMITATE HYDROCHLORIDE FOR ORAL SOLUTIONPresence of Foreign Substance: presence of particles and white flakes in the reconstituted bottles.Heritage Pharmaceuticals Inc · D-0768-2026Class IIOngoingAug 19, 2026CLEAR EYES Maximum Itchy Eye ReliefLack of assurance of sterility. The recall is due to potential contaminationPrestige Brands Holdings · D-0766-2026Class IIOngoingAug 19, 2026SILDENAFIL CITRATE USPCGMP Deviations:Noted during FDA inspectionShoolin Pharma Chem LLP · D-0763-2026Class IIOngoingAug 19, 2026TADALAFIL USPCGMP Deviations:Noted during FDA inspectionShoolin Pharma Chem LLP · D-0762-2026Class IIOngoingAug 19, 2026TADALAFIL USPCGMP Deviations:Noted during FDA inspectionShoolin Pharma Chem LLP · D-0761-2026Class IIOngoingAug 19, 2026TADALAFIL USPCGMP Deviations:Noted during FDA inspectionShoolin Pharma Chem LLP · D-0760-2026Class IIOngoingAug 19, 2026SILDENAFIL CITRATE USPCGMP Deviations:Noted during FDA inspectionShoolin Pharma Chem LLP · D-0759-2026Class IIOngoingAug 19, 2026SEMAGLUTIDE 20mgPresence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialApollo Care, LLC · D-0757-2026Class IIOngoingAug 19, 2026SEMAGLUTIDE 10mgPresence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialApollo Care, LLC · D-0756-2026Class IIOngoingAug 19, 2026SEMAGLUTIDE 7.5mgPresence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialApollo Care, LLC · D-0755-2026Class IIOngoingAug 19, 2026SEMAGLUTIDE 5mgPresence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialApollo Care, LLC · D-0754-2026Class IIOngoingAug 19, 2026SEMAGLUTIDE 2.5mgPresence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialApollo Care, LLC · D-0753-2026Class IIOngoingAug 19, 2026SEMAGLUTIDE 0.9mgPresence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialApollo Care, LLC · D-0752-2026Class IIOngoingAug 19, 2026SEMAGLUTIDE 9mgPresence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialApollo Care, LLC · D-0751-2026Class IIOngoingAug 19, 2026SEMAGLUTIDE 4.5mgPresence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialApollo Care, LLC · D-0750-2026Class IIOngoingAug 19, 2026SEMAGLUTIDE 6.75mgPresence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialApollo Care, LLC · D-0749-2026Class IIOngoingAug 19, 2026SEMAGLUTIDE 2.25MGPresence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialApollo Care, LLC · D-0748-2026Class IIOngoingAug 19, 2026SEMAGLUTIDE 12.5MGPresence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialApollo Care, LLC · D-0747-2026Class IIOngoingAug 19, 2026Diovan (valsartan) 160 mgFailed Dissolution SpecificationsNovartis Pharmaceuticals Corporation · D-0746-2026Class IIOngoingAug 12, 2026Mirabegron Extended-Release TabletsCGMP: Due to Out of Specification (OOS) result for N-Nitroso Mirabegron impurity.Zydus Pharmaceuticals (USA) Inc · D-0745-2026Class IOngoingAug 12, 2026Cyclophosphamide for InjectionPresence of Particulate Matter; identified as stainless steelSunny Pharmtech Inc. · D-0744-2026Class IOngoingAug 12, 2026Cyclophosphamide for InjectionPresence of Particulate Matter; identified as stainless steelSunny Pharmtech Inc. · D-0743-2026Class IIIOngoingAug 12, 2026Total Parental Nutrition - Pediatric PN Patient-Specific TPN BagIncorrect Product FormulationCentral Admixture Pharmacy Services Inc · D-0740-2026Class IIOngoingAug 12, 2026Dicyclomine Hydrochloride Capsulesshortfill; reports of empty capsules.Aurobindo Pharma USA Inc · D-0733-2026Class IIIOngoingAug 5, 2026Dabigatran Etexilate CapsulesFailed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month...Ascend Laboratories, LLC · D-0739-2026